Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

Delayed Quote. Delayed  - 09/30 09:59:33 pm
1.6 USD   +3.23%
09/19 PLURISTEM THERA : Pluristems Phase III Critical Limb Ischemia Study ..
09/15 PLURISTEM THERA : Advances Towards U.S. Clinical Trial in PLX-R18 an..
09/15 PLURISTEM THERA : PSTI) Gears Up For Critical Blood Stem Cell Trial
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2016 09/27/2016 09/28/2016 09/29/2016 09/30/2016 Date
1.62(c) 1.62(c) 1.6(c) 1.55(c) 1.6 Last
84 072 127 764 51 095 146 605 62 720 Volume
-0.61% 0.00% -1.23% -3.13% +3.23% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -31,7 M
Net income 2017 -24,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -33,0 M
Net income 2018 -25,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 0
Capitalization 125 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Latest news on PLURISTEM THERAPEUTICS INC
09/22 PLURISTEM THERAPEUTICS INC. : Pluristem Therapeutics, Inc. - "Biotech Nation"
09/19 PLURISTEM THERAPEUTICS : Pluristems Phase III Critical Limb Ischemia Study Wins ..
09/15 PLURISTEM THERAPEUTICS : Advances Towards U.S. Clinical Trial in PLX-R18 and Ann..
09/15 PLURISTEM THERAPEUTICS INC. (NASDAQ : PSTI) Gears Up For Critical Blood Stem Cel..
09/14 Pluristem Advances Towards U.S. Clinical Trial in PLX-R18 and Announces Princ..
09/12 Pluristem Provides Fiscal Year 2016 Corporate and Financial Highlights
09/09 PLURISTEM THERAPEUTICS : to Conduct Symposium on PLX-PAD Potential for the Treat..
09/08 Pluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peri..
09/07 PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
08/25 PLURISTEM THERAPEUTICS : PSTI) Secures $8 Million EU Grant for Critical Limb Isc..
More news
Sector news : Biotechnology & Medical Research - NEC
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/12 Pluristem Therapeutics net loss improves in FY16
09/12 Pluristem Therapeutics beats by $0.01, revenue in-line
08/02 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
06/22 Midday Gainers / Losers
06/22 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,25 $
Spread / Average Target 110%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Zami Aberman Chairman & Chief Executive Officer
Yaky Yanay President, COO, CFO, Secretary & Director
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Mark S. Germain Director
Nachum Rosman Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS..41.59%125
INCYTE CORPORATION-14.90%17 351
CELLTRION, INC.--.--%11 458
LONZA GROUP AG13.30%10 115
QUINTILES TRANSNATIONA..15.15%9 411
SEATTLE GENETICS, INC.18.74%7 488
More Results